Xencor | XNCR - Прибыль до налогообложения





Прибыль до налогообложения Изменить Дата
AbbVie USD 5.57B 2.9B 2026-03
Alnylam Pharmaceuticals USD 221.65M 60.52M 2026-03
Amgen USD 1.51B 2.41B 2025-12
Arrowhead Research USD 28.27M 7.85M 2025-12
AstraZeneca USD 3.91B 1.28B 2026-03
Biogen USD 377.7M 433.7M 2026-03
Bristol-Myers Squibb USD 1.47B 1.64B 2025-12
Cytokinetics USD -206.03M 23M 2026-03
GlaxoSmithKline GBP 2.14B 919M 2026-03
J&J USD 7.82B 2.86B 2026-03
Karyopharm Therapeutics USD -39.9M 9.01M 2025-12
MacroGenics USD -14.93M 31.75M 2025-12
Merck USD 3.42B 3.32B 2025-12
Novartis USD 3.84B 802M 2026-03
Pfizer USD 5.18B 6.82B 2026-03
Regeneron Pharmaceuticals USD 1.04B 719.6M 2025-12
Roche Holding CHF 4.79B 3.01B 2025-06
Xencor USD -128.64M 124.37M 2026-03